
|Articles|May 31, 2023
In-Clinic Educational Resource on the OAB Treatment Pathway
Advertisement
Please see full
Sponsored by AbbVie US Medical Affairs
Episodes in this series

Now Playing
This content is intended for US/PR Healthcare Professionals.
The Medical Affairs department of AbbVie Inc. is the sole author and copyright owner of this presentation and has paid Urology Times to host this presentation. AbbVie is solely responsible for all written and oral content within this presentation. © 2023 AbbVie Inc. All rights reserved.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA clears Revi Extend implant for urgency urinary incontinence
2
Trial to evaluate ivonescimab plus enfortumab vedotin in urothelial carcinoma
3
Alan Bryce, MD, highlights key phase 3 advances in prostate cancer
4
FDA updates in urology: July 2026
5









